Drug tales and other stories

Paying for the view

BMJ 2008; 336 doi: 10.1136/bmj.39457.434039.59 (Published 17 January 2008)
Cite this as: BMJ 2008;336:160.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ike Iheanacho, editor, Drug and Therapeutics Bulletin
  1. iiheanacho{at}bmjgroup.com

    It’s a wonder they can talk at all, given their mouths are so stuffed with industry gold. Somehow, though, they manage it, and often to great effect.

    Opinion leaders are megastars of the medical world. Groomed, pampered, and promoted by drug companies, they are the role models whose views are to be taken seriously.

    Such individuals are part of an elaborate game that supposedly ensures “transparency” about the relationships between doctors and their industry paymasters. The declarations of competing interests so …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL